# STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

> **NCT05490563** · PHASE2,PHASE3 · TERMINATED · sponsor: **Seelos Therapeutics, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Spinocerebellar Ataxia Type 3

## Interventions

- **DRUG:** SLS-005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05490563
- **Lead sponsor:** Seelos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-03
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** This was a business decision due to financial considerations, not based on data related to safety or therapeutic effects.
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490563, "STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05490563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*